secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2022-07-18T23:59:59+00:00
Accession:  0001193125-22-196384
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem delays ETX-155 Phase 2a MDD trial to Q1 2023 after lower exposure in PSE trial; CMC issue identified
--------------------------------------------------------------------------------

- Lower-than-expected ETX-155 exposure in Phase 1b photosensitive epilepsy trial attributed to CMC batch inconsistencies.
- Phase 1 PK trial in healthy subjects expected Q4 2022 to determine dose for Phase 2a MDD trial.
- Phase 2a MDD trial now expected to start Q1 2023 with topline data in mid-2024.
- Phase 2a PMD trial postponed to preserve investment flexibility; PSE trial paused pending PK data.
- Cash ($149.9M as of March 2022) expected to fund operations and pipeline catalysts through mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312522196384/0001193125-22-196384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312522196384/d385261d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-196384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer